Sherrie and Alan Conover Center for Liver Disease & Transplantation

Medicine & Life Sciences

1. Liver Transplantation 100%
2. Transplants 77%
3. Non-alcoholic Fatty Liver Disease 57%
4. Allografts 50%
5. Transplant Recipients 48%
6. Kidney 40%
7. Kidney Transplantation 36%
8. T-Lymphocytes 33%
9. Tissue Donors 31%
10. Pancreas Transplantation 30%
11. Liver 30%
12. Transplantation 29%
13. Fibrosis 27%
14. Pancreas 25%
15. Hepatocellular Carcinoma 25%
16. Fatty Liver 19%
17. Transplantation Tolerance 18%
18. Graft Rejection 17%
19. Therapeutics 17%
20. Survival 17%
21. Living Donors 17%
22. Graft Survival 16%
23. Immunosuppression 16%
24. Liver Diseases 16%
25. Macrophages 15%
26. Organ Transplantation 14%
27. Neoplasms 14%
28. Tacrolimus 13%
29. Hepatitis C 12%
30. Immunosuppressive Agents 11%
31. Cholangiocarcinoma 10%
32. Mortality 10%
33. Natural Killer Cells 10%
34. End Stage Liver Disease 10%
35. Biopsy 10%
36. Sirolimus 10%
37. Meta-Analysis 10%
38. Cyclosporine 9%
39. Drainage 9%
40. Heart 9%
41. Elasticity Imaging Techniques 9%
42. Regulatory T-Lymphocytes 8%
43. Antibodies 8%
44. Hepacivirus 8%
45. Pancreatic Neoplasms 8%
46. Pancreatitis 8%
47. Psychology Rejection 8%
48. Recurrence 8%
49. Serum 8%
50. Interleukin-15 8%
51. Placebos 7%
52. Interleukin-2 7%
53. Multicenter Studies 7%
54. Systematic Reviews 7%
55. Mycophenolic Acid 7%
56. Incidence 7%
57. Islets of Langerhans Transplantation 6%
58. Liver Cirrhosis 6%
59. Infections 6%
60. Pediatrics 6%
61. Cytokines 6%
62. Quality of Life 6%
63. Liver Neoplasms 6%
64. Insulin 6%
65. Phenotype 6%
66. Coronavirus 6%
67. thymoglobulin 6%
68. Genome 6%
69. Muromonab-CD3 5%
70. Lung 5%
71. Safety 5%
72. Wounds and Injuries 5%
73. Innate Immunity 5%
74. firsocostat 5%
75. Islets of Langerhans 5%
76. African Americans 5%
77. Genes 5%
78. Survival Rate 5%
79. Creatinine 5%
80. Antiviral Agents 5%
81. Interferons 5%
82. Type 1 Diabetes Mellitus 5%
83. Hepatitis B 5%
84. Histocompatibility Antigens Class I 5%
85. Population 5%
86. Alcoholic Hepatitis 5%
87. Obesity 5%